FDAnews Announces -- Real World Evidence and Data: A Tufts Study of 30 Pharma Companies Webinar, August 15, 2019

Thursday, August 1, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Using RWE in the next trial? Experts explain current and planned use of RWE in support of development and post-approval safety studies.

FALLS CHURCH, Va., Aug. 1, 2019 /PRNewswire-PRWeb/ -- Real World Evidence and Data: A Tufts Study of 30 Pharma Companies

An FDAnews Webinar Thursday, Aug. 15, 20191:30-3:00 p.m. EDT https://www.fdanews.com/realworldevidenceanddatatuftsstudy How can an organization use real world evidence (RWE) and real world data (RWD) to generate evidence and identify gaps and challenges? The Tufts Center for the Study of Drug Development (CSDD) study can provide one with valuable insights.

The CSDD investigated 30 biopharmaceutical companies' use of RWD to generate evidence and showed the top measures for using RWE for return on investment, among other findings. It concluded that expanding the use of RWE in regulatory decision-making and increasing sponsors' use of RWD will fill critical gaps related to drug development and safety. The speakers will walk attendees through the study's important takeaways.

Mary Jo Lamberti, PhD, a Tufts University professor and associate director of sponsored research at the CSDD, along with Francis Kendall, a 30-year pharmaceutical industry veteran and senior director at Cytel where he is an instrumental player in the company's Real World Analytics team, will discuss cases of what is being done with RWE and RWD.

Based on their knowledge, and using several recent case studies, Dr. Lamberti and Mr. Kendall will share valuable information on:

  •     Types of technology used to access or collect RWD and evidence and partnerships that support usage
  •     Significant challenges to using RWD as well as strategies and practices that impact return on investment or performance
  •     The key drivers for change and the adoption of RWE
  •     The potential of RWE and how it may be used across the clinical development pipeline
  •     A view on what will happen next in the RWE domain

Understand the critical factors needed to consider in using RWE, and gain insight into the current and planned uses of RWE to support development and post-approval safety studies.

Interested in registering multiple sites? Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally to learn about our special multisite discount.

Webinar Details: Real World Evidence and Data: A Tufts Study of 30 Pharma Companies An FDAnews Webinar Thursday, Aug. 15, 20191:30-3:00 p.m. EDT https://www.fdanews.com/realworldevidenceanddatatuftsstudy?hittrk=19801VOCUS [https://www.fdanews.com/realworldevidenceanddatatuftsstudy __title__ Real World Evidence]

Tuition: $287 per site

Easy Ways to Register: Online: https://www.fdanews.com/realworldevidenceanddatatuftsstudy By phone: 888-838-5578 or 703-538-7600

About FDAnews: FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store